Introduction {#Sec1}
============

Rhinosinusitis (RS) is a condition that arises from inflammation of the nose and the paranasal sinuses resulting in two or more symptoms including nasal blockage, obstruction, congestion, and nasal discharge \[[@CR1]••, [@CR2]••\]. Additional symptoms may include facial pain and pressure, reduction or loss of smell. During diagnosis, endoscopic signs of polyps, mucopurulent discharge, and mucosal obstruction in the middle meatus and computerized tomography (CT) changes within the ostiomeatal complex may be observed \[[@CR2]••\]. RS can be classified into two major types based on the duration and nature of the disease. Acute rhinosinusitis (ARS) involves the presentation of two or more symptoms for the duration of less than 12 weeks, with the damage to the nasal passage being often reversible. On the other hand, chronic rhinosinusitis (CRS) involves remodeling of the nasal passage due to long-standing inflammation causing persistent symptoms for more than 12 weeks \[[@CR2]••, [@CR3]\]. Regardless of duration, both ARS and CRS can be caused by infection by pathogens or allergies against environmental allergens. However, in most cases, the key trigger of RS is often a viral infection that either initiates or exacerbates the symptoms \[[@CR1]••, [@CR2]••, [@CR4]••\].

Epidemiology of ARS and CRS {#Sec2}
===========================

RS is a very common condition encountered in primary care, accounting for about 15% of the population in Western countries \[[@CR4]••\]. The prevalence of ARS is relatively high with an estimated prevalence rate of 6--15% worldwide according to various epidemiological studies \[[@CR2]••, [@CR5]\]. On the other hand, studies on the epidemiology and prevalence of CRS are less comprehensive compared to ARS. This is due to the fact that CRS encompasses many forms of presentation which confound the study parameters when accounting for their prevalence. A prevalence of 5--15% prevalence is estimated both in the USA and Europe based on compilation of available studies \[[@CR2]••, [@CR6]--[@CR9]\].

Pathophysiology and Mechanism of Action of Viral Infection in ARS and CRS {#Sec3}
=========================================================================

The nature of the disease of RS is highly dependent on the predisposing conditions such as allergic rhinitis, nasal deformity, immune deficiency, and other environmental factors. These underlying conditions can be exacerbated following primary damage caused by viral infections and the secondary damage caused by the host response against the virus, resulting in the pathology of RS and its symptoms. In ARS, the primary and secondary damage does not result in permanent changes to the nasal passage, and the ARS symptoms arising from the acute infection typically subside within 12 weeks. On the other hand, when the host responses triggered by the viral infection cause permanent alteration of the anatomy of the nasal passage such as remodeling of the epithelial layer, long-term effects may present in the form of CRS \[[@CR2]••, [@CR3], [@CR10]\].

As the main cause of ARS is viral, the host immune response that leads to the pathophysiology of RS is mainly antiviral in nature. The antiviral immune response involves nonspecific and specific components that require the coordination between different cell types including neutrophils, macrophages, eosinophils, dendritic cells, epithelial cells, mast cells, natural killer cells, and lymphocytes \[[@CR11]••, [@CR12]•\]. An ideal scenario is when the elicited immune response is timely and culminates in early viral elimination and minimal damage to the host. However, the cascade of inflammation initiated by the epithelial cells normally lead to damage by the infiltrating cells, causing edema, engorgement, fluid extravasation, mucus production, and sinus obstruction in the process, eventually leading to ARS or exacerbating ARS \[[@CR1]••, [@CR2]••\].

The exact roles and mechanisms of respiratory viruses in ARS exacerbation are still under debate. It is often speculated that the T-helper 1 (Th1) response is initiated from the epithelial innate immune response via toll-like receptors 3, 7, and 9 (TLR 3, TLR7, and TLR9) due to the virus infection \[[@CR13], [@CR14]••\]. Depending on the type of viral pathogen, the pathogen-sensing molecules in turn activate the production and secretion of nuclear factor-κB (NF-κB), interferon-β (IFN-β), tumor necrosis factor-α (TNF-α), and interleukins-1β, 6, and 8 (IL-1 β, IL-6, and IL-8), which are potent inducers or recruiters of neutrophils and macrophages \[[@CR4]••, [@CR12]•\]. The initial action of neutrophils against virus-infected cells usually contributes to the early symptoms of an acute respiratory virus infection. Following this, the further secretion of TNF-α and interferon-γ (IFN-γ) increases the recruitment of Th1 cells and cytotoxic T-cells which leads to the clearance of the viral pathogens and viral-infected cells. The process of clearing the virus generates dead epithelial and infiltrating cells which contribute to the pathology of ARS. It also creates an environment suitable for secondary bacterial infections (such as *Staphylococcus aureus* and *Streptococcus pneumoniae*), which represent another factor that exacerbates ARS symptoms initiated by a viral infection \[[@CR11]••, [@CR12]•, [@CR15]\].

On the other hand, CRS pathology is not as straightforward as ARS as the former is associated with multiple factors and disease presentations. However, virus infection is known to contribute to and exacerbate CRS. People suffering from CRS often have predisposing factors that contribute to the inflammatory condition in the nasal passage. One factor is the remodeling of the nasal epithelium due to the extended period of inflammation. During viral infection, the similar inflammatory process causes exacerbation as with ARS. In addition, the destruction of the epithelial layer and macrophage recruitment also induce the production of matrix metalloproteinase-9 (MMP-9), a key remodeling protein that mediates repair of the epithelial and extracellular matrix \[[@CR16]\]. The remodeling of the nasal passage in turn exacerbates the symptoms of CRS even further, as normal epithelial function is further diminished due to possible hyperplasia and replacement of epithelial cells with fibroblasts following respiratory viral infection.

Key Viruses Causing the Pathophysiology of ARS and CRS Exacerbation {#Sec4}
===================================================================

Viruses account for at least 80 to 90% of the ARS occurrence, with rhinovirus (RV), respiratory syncytial virus (RSV), influenza virus, coronavirus (CorV), parainfluenza virus (PIV), adenovirus (AdeV), and enterovirus (EV) playing a major role in ARS exacerbation \[[@CR2]••, [@CR4]••, [@CR9]\]. These viruses induce strong Th1 responses which lead to the pathology of ARS exacerbation. In addition, RV and PIV may contribute further to the exacerbation as their infection upregulates ICAM-1, viral receptor for major type of RV \[[@CR17]--[@CR19]\] (Tan et al., unpublished observation). ICAM-1 is also a signaling protein that activates the migration and infiltration of immune cells to contribute further to the exacerbation and pathophysiology of ARS \[[@CR20]\]. RV and CorV are the most common viruses isolated from adult ARS, accounting for approximately 50% of ARS diagnosis. Geographically, there are also other viruses isolated from patients with ARS, e.g., human bocavirus is frequently isolated from ARS cases in Taiwan \[[@CR21]\].

On the other hand, most of the viruses that exacerbate ARS will also cause similar exacerbation in CRS patients. There is a high rate of viral detection from the nasal wash of CRS patients including viruses commonly found in ARS patients, with RV also being the most prevalent virus in CRS exacerbation \[[@CR22]\]. Human bocavirus and metapneumovirus (hMPV) are also found in the nasal washes of CRS patients during flare ups. Moreover, there are also certain viruses (herpes virus, Epstein-Barr virus, and human cytomegalovirus) found in CRS patients with nasal polyps, and it is currently unclear whether they contribute to exacerbation of CRS \[[@CR23]\]. Due to the multifactorial nature of CRS exacerbation, it is relatively harder to identify key viruses that exacerbate CRS compared to ARS, and thus, a direct association between CRS and viral exacerbation is still unclear. The putative underlying mechanism of viral ARS and CRS exacerbation is summarized in Fig. [1](#Fig1){ref-type="fig"} based on existing literature \[[@CR1]••, [@CR2]••, [@CR11]••, [@CR12]•, [@CR14]••\].Fig. 1Putative underlying mechanisms of viral-induced ARS and CRS exacerbation. The figure shows the chain of events leading to ARS and CRS exacerbation from common respiratory virus infections (rhinovirus and influenza virus). When a respiratory virus infects its respective host cells in the nasal epithelium, the intracellular pathogen sensors TLRs 3, 7, and 9 are activated to initiate an antiviral cellular response via the activation of STAT1/2 and NF-κB transcription factors. These activated transcription factors then induce the expression of interferons (IFNs), interferon-stimulated genes (ISGs), chemokines, and cytokines against the virus. The cascade of intracellular events leads to the recruitment of innate responders such as neutrophils, macrophages, and dendritic cells, and in turn activates Th1 adaptive responses against the invading respiratory pathogen. This cascade of inflammatory events against the virus culminates in the symptoms of ARS and its exacerbation, especially if persistent infection occurs due to insufficient viral clearance. Furthermore, the priming of the nasal epithelium against viral infection potentiates its environment to be suitable for secondary bacterial infection which may further exacerbate the symptoms. The infection, if kept unchecked, may result in continued inflammation and expression of remodeling genes that may transition into chronic symptoms of CRS, which increases the susceptibility against further viral infection, causing further exacerbation of symptoms. The putative underlying mechanisms are summarized based on existing literature \[[@CR1]••, [@CR4]••, [@CR11]••, [@CR12]•, [@CR14]••\]. *ARS* acute rhinosinusitis, *CD* cluster of differentiation, *CRS* chronic rhinosinusitis, *DCs* dendritic cells, *IFN* interferon, *IL* interleukin, *ISGs* interferon stimulated genes, *STAT* signaling transducers and activators of transcription, *TLR* toll-like receptor, *MMP* matrix metalloproteinase, *NF-κB* nuclear factor kappa-light-chain-enhancer of activated B cells, *TGF* transforming growth factor, *Th1* T-helper 1

Diagnosis of Viral Infections that Lead to ARS and CRS Exacerbation {#Sec5}
===================================================================

As the cause of RS (especially ARS) is almost exclusively viral in nature, the diagnosis of specific viral infection is important to prevent the unnecessary prescription of antibiotics \[[@CR1]••\]. In clinical practice, most viral infections are usually diagnosed by symptomatic assessment, which lack objective diagnostic tools for confirmation as well as identification of the type of viral infection \[[@CR1]••, [@CR2]••, [@CR9], [@CR15]\]. However, with the development of rapid viral assays and diagnostic kits, viral detection and identification can now be performed within a point-of-care setting for sensitive and specific identification of respiratory virus infections in patients presenting with ARS or CRS exacerbation \[[@CR24]••\]. The current viral detection systems, their features, and use in clinical settings are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Current viral detection systems, their features, and use in clinical settingsDetection methodPrinciple and detectable virusesAdvantagesDisadvantagesCurrent useRapid virus detection by cultureDetecting viral infection in host cells: AdeV influenza A and B PIV 1--4 hMPV RSVWide array of viruses detectedTime-consuming (48-h detection time), host cell specificityShell vial, cluster trays, and similar assays in laboratory attached to hospitalDirect fluorescence antibody testDetecting viral antigens via fluorescence antibody: AdeV influenza A and B PIV 1--3 hMPV RSVSensitive detection of virus in moderate duration (30--60-min detection time)Requires specific training and laboratory spaceImmuno-fluorescence assays conducted in laboratory attached to hospitalRapid antigen direct testDetecting viral antigens via immuno-chromatography: influenza A and B RSVRapid, the only bench-to-bedside clinical diagnosis tool (15--20-min detection time)Prone to false positives and negativesHighly variable sensitivity and specificityBinaxNOW™, Directigen™ Xpect™, and similar products. Rapid antigen test kitsMolecular detectionDetecting specific viral nucleic acid sequences: all respiratory viruses with known sequencesSensitive and specific and allows wide array of virus detection (20--80-min detection time)Requires virus sequence to be known and requires specific training and laboratory spaceMolecular assays (PCR, microarray based) conducted in laboratory attached to hospital*AdeV* Adenovirus, *hMPV* human metapneumovirus, *PIV* parainfluenza virus, *RSV* respiratory syncytial virus

Current assays for rapid detection of respiratory viruses include virus detection, antigen detection, and molecular detection. Rapid virus detection culture such as shell vial or cluster trays facilitate detection of adenovirus, influenza A and B virus, PIV 1--4, hMPV, and RSV within 48 h \[[@CR25]\]. Assays for virus antigen detection involve the use of viral antigen-specific antibodies using direct fluorescence antibody test and rapid antigen test. The direct fluorescence antibody test can detect AdeV, influenza A and B virus, hMPV, PIV, and RSV within 30 to 60 min \[[@CR26]\], while the rapid direct antigen test utilizes immuno-chromatographic antibody detection kits that are simple to perform (detection in 15--20 min), but so far limited only for detecting influenza A and B virus and RSV \[[@CR27], [@CR28]\]. Lastly, molecular detection includes amplification of viral nucleic acid sequences through polymerase chain reaction of patient samples. This assay can detect respiratory viruses with high sensitivity and specificity within a short time frame of 20 to 80 min \[[@CR29]\] and are recognized to play important roles in respiratory viral diagnosis due to their versatility \[[@CR24]••, [@CR30], [@CR31]\]. In addition to the above methods, there is also serological detection such as ELISA which detects antibodies against the virus. However, while serological detection was widely used in the current diagnostic settings, it is not suitable for the diagnostics of acute infections that caused ARS and CRS exacerbations, and therefore not discussed in this review.

Currently, rapid culture, direct fluorescence antibody, and molecular detection necessitate specialized laboratories attached to larger hospitals to perform the diagnosis and identification of viruses causing ARS and CRS exacerbation, due to the complexity and training to operate such assays. The point-of-care detection method is the rapid direct antigen test through immuno-chromatography, but this test suffers from sensitivity issues and may lead to false negatives and misdiagnosis \[[@CR32], [@CR33]\]. Therefore, it is imperative to continue to improve diagnostic kits to rapidly and accurately pinpoint the causative agents of ARS or CRS exacerbation to prevent inappropriate prescriptions for treatment of exacerbation episodes, especially the misuse of antibiotics for viral-induced exacerbation of ARS and CRS.

Prevention and Treatment of Viral Exacerbation of ARS and CRS {#Sec6}
=============================================================

The clinical management of ARS and CRS exacerbation due to virus infection should be similar for any episodes of ARS and CRS exacerbation. Treatment usually aims to resolve and relieve the symptoms while the infection resolves itself. Symptomatic treatment involves the use of nasal decongestants and topical corticosteroids to relieve nasal congestion and to reduce nasal edema \[[@CR34]\]. Nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used to decrease inflammation arising from viral infection to relieve symptoms such as fever and nasal edema \[[@CR2]••\]. When secondary bacterial infection is suspected, narrow-spectrum antibiotics such as amoxicillin can be prescribed. In addition to symptomatic management and relief, treatment and prevention of ARS and CRS exacerbation can be further enhanced with advances in viral detection to identify the exact viral etiology. By using antiviral treatments, viral load in the nasal epithelium can be reduced and therefore further lowering the inflammation associated with the infection, reducing RS symptoms and its duration. Hence, it is possible to add currently available antivirals to the repertoire of preventive and therapeutic strategies to counter viral exacerbation episodes of ARS and CRS.

From the perspective of exploiting antiviral agents to prevent or treat ARS and CRS exacerbation, influenza virus infection has the widest array of therapies. While the adamantane derivatives amantadine and rimantadine that blocks influenza fusion is currently not recommended as a treatment due to widespread resistance \[[@CR35], [@CR36]\], there are still multiple neuraminidase inhibitors specific against influenza viruses that are available as therapeutic agents for severe episodes of ARS and CRS exacerbation. For example, oseltamivir, laninamivir, peramivir, and zanamivir specifically inhibit the replication of influenza viruses, and thus prevent or minimize the effects of ARS and CRS exacerbation \[[@CR37]•, [@CR38]••\]. Such treatments may be harnessed as useful prophylaxis during influenza season for patients with severe episodes of ARS or CRS exacerbation. In addition to neuraminidase inhibitors, annual influenza vaccination can also serve as a means of preventing ARS and CRS exacerbation due to influenza virus infection.

On the other hand, other common respiratory infections due to RV, PIV, RSV, CorV, and AdeV do not have suitable vaccines and have limited antiviral agents that can be used against them. Palivizumab is a monoclonal antibody targeting the fusion of RSV and is used as a prophylaxis for infants at high risk of morbidity or mortality from RSV complications \[[@CR39]\]. There are also broad-spectrum antivirals such as ribavirin that prevent viral RNA synthesis that can be used against influenza virus, RSV, PIV, and to a certain extent, coronavirus, but are only reserved for severe cases due to their undesirable adverse effects \[[@CR40], [@CR41]\]. Similarly, cidofovir, a DNA synthesis inhibitor is used against disseminated adenovirus infection as a last line of defense against severe adenovirus disease due to concerns on its toxicity. To date, noninfluenza antivirals against respiratory viruses are still in the early stages of development and may not yet be optimal for the prevention and management of viral ARS and CRS exacerbation \[[@CR37]•\].

Notwithstanding this, there are also investigational agents in clinical trial phases and are close to being available clinically. These treatments may be useful in the near future to treat respiratory viral infections to manage viral ARS and CRS exacerbation. Favipiravir (T-705) has so far been tested to be efficacious against influenza virus and is being evaluated for other RNA viruses and was recently approved in 2014 to be marketed in Japan for severe influenza \[[@CR42], [@CR43]\]. Fludase (DAS181), a fusion protein that prevents influenza infection, is currently in phase II clinical trials \[[@CR44], [@CR45]\]. Presatovir (GS-5806), ALS-8176, and ALN-RSV01 are all inhibitors of RSV replication that are undergoing trials as potential treatment against RSV \[[@CR46]--[@CR49]\]. If found to be efficacious with minimal side effects, these investigational agents can be exploited in the future as effective measures in managing viral exacerbation of ARS and CRS \[[@CR38]••\]. Detailed information on the current antiviral drugs against respiratory viruses and their mechanisms of action is discussed in Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}.Fig. 2Current antiviral drugs against respiratory viruses and their mechanisms of action. The figure shows a representative respiratory virus infection (influenza) in the host cell. Other than vaccines, which do not act directly on viral replication in the host cell, other antivirals target specific virus components required for the replication cycle: (*1*) viral entry receptor---fludase; (*2*) viral fusion---presatovir, palivizumab; (*3*) preventing transcription/replication---ribavirin, taribavirin, cidofovir, favipiravir, ALS-8176; (*4*) preventing translation---ALN-RSV01; (*5*) preventing viral excision---oseltamivir, laninamivir, peramivir, zanamivir. The antivirals and their mechanisms are summarized based on existing literature \[[@CR37]•, [@CR38]••, [@CR39]--[@CR41]\]. *mRNA* messenger RNA, *vRNP* viral ribonucleoprotein, *siRNA* small interfering RNA, *ALS-8176* deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine, *ALN-RSV01* asvasiran sodium Table 2Current and experimental antiviral agents against respiratory virusesManagementMarket nameRespiratory virus pathogen efficacious againstMode of actionCurrent FDA-approved usage OR at research development stageVaccination Annual influenza vaccination*Multiple*Influenza virusBoosting immune response for influenza-specific antibody productionPreventive prophylaxis during influenza seasonFusion inhibitors Amantadine*Symmetrel*®Influenza virusPrevents viral fusion and release of nucleic acidInfluenza virus infection (discontinued) Rimantadine*Flumadine*® Palivizumab*Synagis*®Respiratory syncytial virusRespiratory syncytial virus infectionNeuraminidase inhibitors Oseltamivir*Tamiflu*®Influenza virusInhibits influenza neuraminidase to prevent viral release and replicationInfluenza virus infection Laninamivir*Inavir*® (Japan) Peramivir*Rapiacta*®*PeramifluRapivap*® Zanamivir*Relenza*®Guanosine analogue Ribavirin*Copegus*®Influenza virusRespiratory syncytial virusParainfluenza virusCoronavirusBlocks viral RNA synthesisHepatitis C infection*Pegasys*® Taribavirin*Viramidine*®DNA/RNA polymerase inhibitor Cidofovir*Forvade*® *Vistide*®AdenovirusBlocks viral DNA polymeraseCytomegalovirus retinitis Favipiravir (T-705)*Avigan*® (Japan)Influenza virusInhibits viral polymeraseInfluenza virus infectionExperimental drugs Experimental drug Fludase (DAS181)NilInfluenza virusParainfluenza virusCleaves cell receptor required for viral entryPhase II clinical trial Experimental drug Presatovir (GS-5806)NilRespiratory syncytial virusInhibits fusion of virus in host cellsPhase II clinical trial Experimental drug ALS-8176NilRespiratory syncytial virusRSV polymerase inhibitorPhase II clinical trial Experimental drug ALN-RSV01NilRespiratory syncytial virussiRNA targeting RSV transcriptsPhase II clinical trial*ALS-8176* deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine, *ALN-RSV01* asvasiran sodium

Conclusion {#Sec7}
==========

ARS and CRS remain a considerable economic and public health burden worldwide due to their high prevalence. As virus infections are now established as the key cause of most cases of RS and exacerbation (especially ARS), more attention should be focused on the proper study, diagnosis, prevention, management, and treatment of viral-induced exacerbation of ARS and CRS symptoms. A more detailed perspective of the virology of ARS and CRS exacerbation can enhance our current understanding of RS to improve the quality of treatment of episodes of ARS and CRS exacerbation, as well as to minimize and prevent the misuse of antibiotics in the treatment of ARS and CRS exacerbation, which may contribute to the growing spectrum of antibiotic resistance.
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